Linear Iga Dermatosis / Chronic Bullous Disease of Childhood
Linear Iga Dermatosis / Chronic Bullous Disease of Childhood
Linear Iga Dermatosis / Chronic Bullous Disease of Childhood
Dermatosis / Chronic
Bullous Disease of
Childhood
2
EPIDEMIOLOGY
4
CLINICAL FINDINGS
5
CLINICAL FINDINGS
▫ Chronic Bullous Disease of Childhood
⬝ Tense bullae on an inflammatory base
⬝ AOP: perineum and perioral region
⬝ Occur in clusters > "cluster of jewels”
appearance
⬝ New lesions > appear around the periphery of
previous lesions > '"collarette" of blisters
⬝ (+) Pruritus and/or a burning of the skin
⬝ Mucosal involvement is less often seen
⬝ Good Prognosis
6
CLINICAL FINDINGS
▫ Mucosal involvement
⬝ Asymptomatic oral ulcerations & erosions >
severe conjunctival and oral disease
⬝ Oral lesions seen in 70% of patients with LIGA
⬝ Mucosal invasion with complications is less
often seen in CBDC
⬝ Less prominent in patients with druq-
induced linear IGA
7
DISEASE ASSOCIATIONS
⬝ Association with Gluten-sensitive enteropathy (?)
⬝ Clinical manifestations have not been controlled by the use of a gluten-free diet,
⬝ No circulating autoantibodies against tissue transglutaminase
⬝ Other conditions
⬝ Ulcerative colitis
⬝ Crohn's disease
⬝ Acute mononucleosis (CBDC)
⬝ Paecilomyces lung infection (CBDC)
⬝ Malignancies
⬝ IgA nephropathy
⬝ Physical exposures: Ultraviolet light
DISEASE ASSOCIATIONS
▫ Drugs: Vancomycin, Lithium Phenytoin,
Sulfamethoxazole/Trimethroprin, Furosemide,
Atorvastatin, Captopril, And Diclofenac.
▫ Subepidermal blister
▫ with collections of neutrophils linearly aligned
along DEJ, often accumulating at the papillary tips
▫ Superficial perivascular and interstitial neutrophilic
infiltrates admixed with occasional eosinophils and
lymphocytes
▫ WITHOUT any evidence of neutrophilic vasculitis
10
HISTOPATHOLOGY
11
12
CLINICAL COURSE AND PROGNOSIS
⬝ CDC is most often a self-limited disease, with most children going into remission
within 2 years of the onset of the disease.
⬝ May persist well into puberty but often is less severe than the initial eruption.
14
Dermatitis
Herpetiformis
EPIDEMIOLOGY
⬝ M>F
⬝ May start at any age
⬝ most common: 2nd to 4th decade of life
⬝ Persists indefinitely with varying severity
⬝ Patients usually have asymptomatic gluten-sensitive
enteropathy (celiac disease).
ETIOLOGY AND PATHOGENESIS
17
CLINICAL FINDINGS
▫ Primary lesion: INTENSELY PRURITIC
⬝ Erythematous papule
⬝ Urticaria-like plaques
⬝ Vesicle (most common)
▫ Post inflammatory hypo or hyperpigmentation
▫ Localized stinging, burning, itching (8-12 hours
▫ before appearance of lesions)
▫ SYMMETRIC distribution: elbows, knees,
▫ buttocks, shoulders, and sacral areas
⬝ May affect scalp, posterior nuchal area, face
▫ Mucous membranes rare
18
CLINICAL FINDINGS
19
CLINICAL FINDINGS
20
HISTOPATHOLOGY
▫ Early Skin Lesion (Clinically non-vesicular)
⬝ Separation of papillary tips from overlying
epidermis
⬝ Dermal papillary collection of neutrophils
(microabscesses)
⬝ Neutrophilic fragments
⬝ Varying numbers of eosinophils
⬝ Fibrin
⬝ Superficial to mid perivascular lymphohistiocytic
infiltrates with some neutrophils and occasional
eosinophils
21
HISTOPATHOLOGY
▫ Older Skin Lesion
⬝ Subepidermal vesicles
⬝ DDx: (subepidermal bullous eruptions)
⬝ Bullous Pemphigoid
⬝ Erythema Multiforme
⬝ Bullous Drug Eruption
⬝ Pemphiqoid Gestationis
22
HISTOPATHOLOGY
▫ - Immunoglobulin A (IgA)
⬝ GRANULAR IgA deposits in dermal
papillary tips of normal appearing skin,
perilesional, uninvolved skin
⬝ Most reliable criterion for diagnosis
⬝ Mostly IgA1 produced in bone marrow
⬝ IgA1 is the predominant subclass
targeting dietary proteins of gut secretions
w/ DH
⬝ IgA2 produced in mucosal sites
23
SULFONES
⬝ Dapsone (Diaminodiphenyl sulfone)
⬝ Initial: 100-150mg/d OD
⬝ Rarely: 300-400mg/d for initial improvement
⬝ Take the minimal dose required to suppress signs & symptoms
⬝ Some pts: 25mg/week is sufficient
⬝ Sulfoxone (Diazone)
⬝ Not available in the US
⬝ Sulfapyridine
⬝ 1-1.5g/d
⬝ Indications: Dapsone intolerance, Elderly, Cardiopulmonary problems
⬝ Not available in the US
TREATMENT
31